14998 Reductions in absolute PASI over 144 weeks of treatment with certolizumab pegol in patients with plaque psoriasis: Pooled analysis from two phase 3 trials (CIMPASI-1 and CIMPASI-2)

Abstract

Background: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti–tumor necrosis factor. Here, we report the proportions of patients with moderate to severe plaque psoriasis (PSO) achieving clinically relevant absolute PASI thresholds over 144 weeks’ CZP treatment.